A new study from Professor Vadim Backman shows that restoring cellular memory prevents cancer cells’ ability to adapt to evade treatment.

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a cancer ...

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer ...

Benign and cancerous calcium phosphate deposits that may look identical on a mammogram have distinct differences in their ...

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

ASCO 2025, bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guérin (BCG) therapy, IL-15RαFc Superagonist SHR-150, IL-15RαFc Superagonist SHR-1501 with or Without Bacille ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

Interleukin 12 (IL-12) is an immunostimulatory cytokine with proven antitumour effect in animal models. Despite evidence indicating its biological effect in humans, neither the recombinant protein nor ...